Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Watson-Marlow Pumps Group Acquires Bio Pure Technology Limited

Published: Tuesday, January 07, 2014
Last Updated: Monday, January 06, 2014
Bookmark and Share
WMPG strengthens its single-use biopharmaceutical offering through acquisition of Bio Pure.

Watson-Marlow has acquired Bio Pure through its parent company Spirax-Sarco Engineering plc for £8.5 million. Bio Pure, based in Portsmouth UK, specializes in the design and production of advanced single-use tubing connector systems for biopharmaceutical customers.

Bio Pure is a natural extension of the Watson-Marlow peristaltic pump range, complementing its offering in the Biopharmaceutical sector, and joining a portfolio comprising Watson-Marlow Pumps, Watson-Marlow Tubing, Flexicon Filling Systems, Alitea OEM Pumps MasoSine Process Pumps and Bredel Hose Pumps.

WMPG already has a positive commercial relationship with Bio Pure, jointly promoting Watson-Marlow pumps, tubing and Bio Pure connectors to shared customers, where both Bio Pure and Watson-Marlow products are integrated into customers’ equipment. There is clear synergy and a significant growth opportunity presented by bringing together Bio Pure’s product range and WMPG’s products to meet the needs of the rapidly growing single-use biopharmaceutical market.

The acquisition strengthens WMPG’s presence in the biotechnology and pharmaceutical industries. In particular, Bio Pure complements WMPG’s existing range of Flexicon peristaltic filling systems and single use tubing, easing customer validation in demanding contamination-free dispensing applications and offering improved sterility for critical applications.

Jay Whalen, President of the Watson-Marlow Pumps Group comments: "The strategic acquisition of Bio Pure further broadens our product range and strengthens Watson-Marlow's position in the single-use biopharmaceutical market. That enables us to provide a more comprehensive and improved service to our customer looking for sterility throughout their fluid path. This is yet another exciting milestone for Watson-Marlow and we are looking forward to accelerating our growth within the biopharmaceutical market with our broadened product portfolio coupled to our process expertise.”

Biopure was established in 1998 by the founder, Roy Maunder, who will continue with the company as a Non-Executive Director. We are pleased that Mr Steven Feasey will continue as Sales Director.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Envigo Rat Models Proven to be Susceptible to Intra-Vaginal HSV-2 Infection and Protectable
Scientific findings establish the effectiveness of new approach to investigate the protective effects of vaccine candidates and anti-viral microbodies and to study asymptomatic primary genital HSV-2 infection.
Drug that Activates Innate Immune System Identified
Researchers from the institute have identified a drug, which is straightforward to synthesize and to couple to antigens that induce an immune response and may prove useful in the generation of vaccines.
Valvena, GSK Sign New R&D Collaboration
Valneva to supply process development services for EB66® -based Influenza vaccines.
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Therapeutic Approach Gives Hope for Multiple Myeloma
A new therapeutic approach tested by a team from Maisonneuve-Rosemont Hospital (CIUSSS-EST, Montreal) and the University of Montreal gives promising results for the treatment of multiple myeloma, a cancer of the bone marrow currently considered incurable with conventional chemotherapy and for which the average life expectancy is about 6 or 7 years.
Protein Protects Against Flu in Mice
The engineered molecule doesn’t provoke inflammation and may hail a new class of antivirals.
Crowdfunding the Fight Against Cancer
From budding social causes to groundbreaking businesses to the next big band, crowdfunding has helped connect countless worthy projects with like-minded people willing to support their efforts, even in small ways. But could crowdfunding help fight cancer?
Natural Protein Points to New Inflammation Treatment
Findings may offer insight to effective treatments for inflammatory diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
Tricked-Out Immune Cells Could Attack Cancer
New cell-engineering technique may lead to precision immunotherapies.
Therapy Halts Progression of Lou Gehrig’s Disease
Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, for nearly two years in one type of mouse model used to study the disease – allowing the mice to approach their normal lifespan.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!